Key result
Subacute preemptive TEVAR optimizes aortic remodeling with lower perioperative risk in high-risk uncomplicated TBAD.
Why the study?
Patients with uncomplicated Stanford type B aortic dissection have heterogeneous long-term outcomes, creating clinical uncertainty regarding whether and when to perform preemptive TEVAR to treat high-risk patients while avoiding overtreatment in low-risk patients.
Does preemptive thoracic endovascular aortic repair (TEVAR) during the subacute phase improve long-term aortic remodeling and reduce late aorta-related events compared to best medical therapy alone or acute-phase intervention in high-risk patients with uncomplicated Stanford type B aortic dissection?
Does preemptive thoracic endovascular aortic repair (TEVAR) during the subacute phase improve long-term aortic remodeling and reduce late aorta-related events compared to best medical therapy alone or acute-phase intervention in high-risk patients with uncomplicated Stanford type B aortic dissection?
This narrative review synthesizes evidence supporting the subacute phase (15-90 days) as the optimal window for preemptive TEVAR in carefully selected, high-risk patients with uncomplicated type B aortic dissection after initial stabilization with medical therapy.
Answers are grounded in this paper and cite their sources.
Supports selective subacute TEVAR timing in high-risk uTBAD; leaves open need for prospective trials before practice change.
As the indications for thoracic endovascular aortic repair (TEVAR) in the treatment of type B aortic dissection continue to expand, whether and when patients with uncomplicated Stanford type B aortic dissection (uTBAD) should undergo preemptive TEVAR have become pressing clinical questions. Although uTBAD is not accompanied by complications such as rupture or malperfusion during the acute phase, some patients develop persistent false lumen perfusion, aortic dilatation, and late aorta-related events during follow-up, resulting in heterogeneous long-term outcomes. Therefore, avoiding overtreatment in low-risk patients while accurately identifying high-risk patients who may benefit from intervention is essential for improving long-term aortic outcomes. This review first analyzes the optimal timing of preemptive TEVAR based on disease staging, pathological changes in the aortic wall, and current clinical evidence, with particular emphasis on the rationale for the subacute phase as a potential treatment window. It then summarizes the clinical features, morphological characteristics on CTA, false lumen status, and dynamic imaging assessment methods associated with high-risk uTBAD. Finally, it highlights the need to develop multimodal predictive models to enable more precise patient selection and individualized intervention.
No takes yet. Share an insight, caveat, or question.
<p>Renzhe Wang<sup>1,2</sup>, Zhixiang Liao<sup>1</sup>, Birun Huang<sup>1</sup></p> (2026) conducted a review in Uncomplicated Stanford type B aortic dissection (uTBAD). Preemptive thoracic endovascular aortic repair (TEVAR), particularly during the subacute phase (15-90 days) vs. Best medical therapy (BMT) alone or TEVAR at other timing stages (hyperacute, acute, or chronic) was evaluated on Aortic remodeling, long-term aorta-related events, and perioperative safety. Preemptive TEVAR in the subacute phase (15-90 days) balances preserved aortic plasticity and lower perioperative risk for carefully selected high-risk uTBAD patients stabilized on medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: